Mass Tort Advertising
Glossary

The decline in campaign performance caused by a target audience being overexposed to the same creative assets. In mass tort advertising, ad fatigue is particularly acute in small injury pools where the same claimants see the same ads repeatedly. Countered through creative rotation, audience exclusions, and new angle testing.

A harmful outcome reported in connection with the use of a drug, medical device, or product. Adverse event data from the FDA's FAERS database is a primary input in causation analysis for pharmaceutical mass torts. A disproportionate reporting ratio (PRR or ROR) above threshold is a key early signal for emerging tort viability. See also: FAERS, Bradford Hill Criteria.

Firefighting foam used extensively by military installations and airports since the 1960s, found to contain PFAS compounds linked to cancer. AFFF litigation is one of the largest active mass tort dockets, with tens of thousands of cases consolidated in federal MDL. Strong entry window for military veterans and airport workers with qualifying diagnoses.

The practice of removing existing claimants, prior converters, or disqualified prospects from active ad targeting pools. Proper exclusion lists prevent wasted spend, reduce duplicate intake, and improve ROAS. In mass tort campaigns, exclusion of signed retainers is essential to avoid paying to re-acquire claimants already in the funnel.

A qualifying intake criterion in addiction-related torts (social media, video games, sports betting) specifying that a claimant must have begun using the product before a defined age, typically under 18. This criterion establishes the minor exposure element central to negligence and failure-to-warn claims in these dockets.

A small set of test cases selected within an MDL to be tried first, providing juries and parties with a realistic sense of case value and litigation risk. Bellwether verdicts are the single most important pricing signal for mass tort settlements. A plaintiff win in bellwether proceedings typically triggers a surge in campaign activity and claimant acquisition costs.

A set of nine epidemiological criteria used to evaluate whether an observed association between an exposure and a disease is likely causal. Applied in mass tort causation analysis to score scientific evidence linking a defendant product to plaintiff injuries. Criteria include strength of association, consistency, specificity, temporality, biological gradient, plausibility, coherence, experiment, and analogy. Used in TortIntel's Causation Lab scoring engine.

The larger group of cases from which bellwether trial selections are made. Being included in the bellwether pool increases a case's leverage in settlement negotiations. Law firms advertising aggressively during early MDL phases often have cases selected for the bellwether pool, giving their dockets disproportionate influence over global settlement value.

The percentage of inbound claimant leads who exit the intake process without completing qualification. A high bounce rate signals a misalignment between ad creative, landing page messaging, and intake criteria — or a friction-heavy qualification flow. Reducing bounce rate is typically more efficient than increasing ad spend.

The rate at which a tort campaign acquires signed retainers relative to the total available claimant pool. High velocity campaigns are those that front-load acquisition during the optimal entry window before market saturation. Velocity is a function of budget allocation, creative performance, and intake conversion rate. See also: Entry Window.

Any piece of scientific, epidemiological, or clinical evidence suggesting a causal link between a defendant product and plaintiff injury. Strong causation signals — published studies, FAERS disproportionality, expert consensus — are necessary preconditions for a viable mass tort docket. Weak causation signals indicate elevated litigation risk regardless of intake volume. Monitored continuously in TortIntel.ai.

An individual who asserts they were harmed by a defendant's product, drug, device, or conduct, and who may be eligible to participate in mass tort litigation. The term is preferred in advertising contexts over "plaintiff" because not all claimants will ultimately file suit — many resolve through settlement before formal litigation.

A lawsuit in which a representative plaintiff sues on behalf of a large group of similarly situated individuals. Distinct from mass tort litigation — class actions require common legal and factual questions and a single recovery shared among class members. Mass torts preserve individual case values and are generally superior for cases involving significant personal injury.

The business model in which a referring ("originating") law firm signs clients through advertising and refers them to a national litigation firm under a co-counsel agreement. The originating firm earns a referral fee (typically 25–40% of attorney's fees) without handling the litigation. This model is the financial engine for most mass tort advertising campaigns. See also: Referral Fee.

Ad creative designed to satisfy both platform policies (Meta, Google) and state bar attorney advertising rules. Mass tort ads operate under dual compliance requirements — platform policies prohibit certain health claims and emotional manipulation, while state bar rules govern disclaimers, attorney-client formation, and truthfulness standards. MTAA maintains a compliance creative framework across all active campaigns.

Meta's server-side event tracking system that sends conversion data directly from a server to Meta, bypassing browser-based pixel limitations caused by ad blockers and iOS privacy changes. CAPI is essential for accurate optimization in mass tort campaigns, where claimant privacy concerns and health-related browsing create higher rates of tracking signal loss than in typical consumer verticals.

The total advertising and intake expenditure required to acquire one signed retainer that meets full case qualification criteria. Distinct from cost-per-lead, which measures only inbound contacts. CPC is the primary efficiency metric in mass tort advertising. In well-run campaigns, CPC ranges from $400 to $2,000+ depending on tort type, qualification stringency, and market saturation.

The average advertising cost to generate one inbound claimant inquiry, regardless of whether the lead qualifies or signs. CPL is a useful efficiency metric for creative and audience optimization but is meaningless without a corresponding conversion-to-retainer rate. Low CPL with low conversion produces poor CPC. See also: Cost Per Case.

The federal evidentiary standard governing the admissibility of expert witness testimony. Under Daubert, a judge acts as gatekeeper to ensure expert opinions are based on sufficient facts, a reliable methodology, and a valid application of that methodology. In mass tort litigation, Daubert challenges to plaintiff causation experts can eliminate entire dockets — making scientific causation the primary litigation risk factor.

Pfizer's injectable contraceptive linked in studies to increased meningioma risk. Active mass tort litigation as of 2025–2026 with cases consolidating in federal court. Qualifying criteria include long-term use (typically 12+ months) and a qualifying meningioma diagnosis. Strong early entry window for firms building dockets.

The collection of signed cases a law firm holds in a particular mass tort litigation. "Building a docket" refers to the process of advertising, qualifying claimants, and accumulating signed retainers in anticipation of MDL consolidation and eventual settlement. Docket size and case quality are the primary determinants of a firm's settlement leverage.

An automated sequence of email and SMS touchpoints delivered to prospects or existing clients over time to drive conversion or re-engagement. In the mass tort context, drip campaigns are most commonly deployed against a law firm's existing client database to identify clients who may qualify for new tort campaigns — the model used by TortDrip.com.

The ethical conflict that arises when a law firm represents multiple claimants in the same tort with potentially adverse interests in allocation of a global settlement. Firms managing large dockets must maintain conflict protocols and ensure individual client interests are protected in aggregate settlement negotiations.

The period in a tort's litigation lifecycle during which new claimants can be acquired at cost-effective rates before the market saturates. Entry windows are defined by four convergent factors: sufficient scientific causation evidence, early MDL filing activity, manageable competitive spend density, and an intact statute of limitations for most potential claimants. The entry window concept is central to MTAA's campaign timing methodology and is scored in the Jacob Score.

Mass tort litigation against commercial sterilization facilities that allegedly exposed surrounding communities to ethylene oxide, a known carcinogen linked to lymphoma and breast cancer. Qualifying criteria include residential or work proximity to a facility and a qualifying cancer diagnosis. Cases are geographically concentrated around facilities identified by the EPA.

Factors that disqualify an otherwise interested claimant from a mass tort campaign. Common exclusion criteria include prior settlement of the same claim, statute of limitations expiration, absence of a qualifying injury, and failure to meet minimum exposure duration requirements. Rigorous exclusion criteria reduce case acquisition costs but tighten the qualifying claimant pool. See also: Intake Criteria.

The FDA's database of adverse event reports submitted by healthcare providers, manufacturers, and patients following use of drugs and medical devices. FAERS contains over 10 million reports and is a primary source for early causation signal detection. Disproportionality analysis (PRR, ROR) of FAERS data identifies drug-event combinations reported at rates significantly above background — a key input in the TortIntel Causation Lab.

The dominant claimant acquisition channel for mass tort plaintiff firms, accounting for the majority of new signed retainers in most active dockets. Facebook's combination of broad demographic reach, detailed behavioral targeting, and video creative capabilities makes it uniquely effective for reaching tort-eligible populations. MTAA pioneered the use of Facebook advertising for mass tort law firms beginning in 2013. See also: Meta Advertising.

MTAA's proprietary early-warning system within TortIntel.ai that monitors emerging tort signals — new adverse event patterns, litigation filings, regulatory actions, and scientific publications — before they achieve mainstream awareness. FireWatch alerts allow early-mover firms to begin docket building before competitive advertising density drives up acquisition costs.

An integrated approach to claimant acquisition that encompasses every stage from initial ad impression through signed retainer delivery. Full-funnel management includes creative development, media buying, landing page optimization, intake operations, e-signature, and case quality monitoring. The alternative — fragmented vendors at each funnel stage — typically results in attribution gaps, cost inflation, and quality degradation. MTAA operates a full-funnel model with a transparent 15% management fee.

A negotiated resolution that resolves all or substantially all cases in a mass tort docket in a single transaction. Global settlements are typically structured as settlement funds with allocation formulas that assign case values based on injury severity, exposure duration, and other qualifying factors. Achieving a global settlement is the terminal event of most mass tort litigation cycles.

Mass tort litigation against manufacturers of GLP-1 receptor agonist drugs (semaglutide, tirzepatide) including Ozempic, Wegovy, and Mounjaro, alleging failure to warn about the risk of severe gastrointestinal conditions including gastroparesis. One of the largest active tort dockets by intake volume as of 2025–2026.

Mass tort litigation alleging that chemical hair straightening and relaxer products containing endocrine-disrupting compounds caused uterine cancer, ovarian cancer, and other reproductive injuries. Cases are consolidated in federal MDL. Qualifying criteria include regular use history and a qualifying cancer diagnosis.

The practice of building mass tort ad audiences and intake flows without triggering HIPAA's restrictions on the use or disclosure of protected health information. Because mass tort claimants often disclose health conditions through lead forms and intake calls, proper data handling protocols — including BAA execution with vendors — are legally required for plaintiff firms and their marketing partners.

Mass tort litigation against manufacturers of surgical hernia mesh products that allegedly caused complications including mesh migration, infection, bowel obstruction, and chronic pain requiring revision surgery. Multiple separate MDLs exist for different manufacturers. A mature docket with well-established case values and qualification criteria.

The specific qualifying requirements a claimant must meet to be accepted into a mass tort campaign as a signed retainer. Criteria are set by the national litigation firm and typically include product use confirmation, injury type and severity thresholds, exposure duration minimums, and statute of limitations eligibility. Intake criteria directly determine campaign economics — tighter criteria produce higher-value cases but lower conversion rates. Compare tort criteria side-by-side at compare.mtaa.ai.

The rate at which inbound claimant leads are processed through qualification and converted to signed retainers. Intake velocity is critical because claimant motivation decays rapidly — the longer the gap between ad response and retainer execution, the lower the conversion rate. Best-in-class intake operations achieve same-day retainer execution on qualified leads.

Mass tort litigation against manufacturers of inferior vena cava blood clot filters that allegedly fracture, migrate, or perforate organ walls. A mature docket with established settlement values. Qualifying criteria include retrievable filter implantation and documented filter fracture, migration, or resulting injury confirmed by imaging.

A proprietary 0–100 composite investment signal developed by Jacob Malherbe at Mass Tort Ad Agency for evaluating mass tort campaign viability. The score aggregates four weighted dimensions: Scientific Causation (25%), Litigation Maturity (30%), Intake Viability (25%), and Timeline (20%). A Jacob Score above 70 indicates an actionable entry window; below 40 indicates pre-litigation or over-saturated conditions. Scores are updated in real time in TortIntel.ai.

A dedicated web page optimized to convert claimant ad traffic into qualified leads or completed intake forms. Mass tort landing pages must balance regulatory compliance (attorney advertising disclosures), HIPAA data handling requirements, and conversion optimization. The strongest mass tort landing pages lead with injury validation before introducing legal context.

The practice by some mass tort marketing vendors of charging law firms more per lead than the underlying media cost, pocketing the spread as undisclosed profit. Lead markup is a primary driver of cost-per-case inflation in the industry and is structurally misaligned with client interests. The transparent 15% management fee model used by MTAA eliminates lead markup entirely.

Third-party funding provided to law firms or plaintiffs in exchange for a portion of the eventual settlement or verdict proceeds. In mass tort litigation, litigation finance enables plaintiff firms to fund advertising, intake, and case development costs before receiving settlement proceeds. The cost of litigation finance (typically 20–40% of funded amount) is a significant drag on attorney fee economics that must be modeled into campaign ROI calculations.

One of the four components of the Jacob Score, measuring the stage of a tort's legal development from pre-filing through global settlement. Maturity milestones include: first filed cases, MDL formation, bellwether selection, bellwether verdict, and settlement fund creation. Campaigns launched at optimal maturity — after MDL formation but before bellwether verdicts — typically achieve the best combination of case value and intake economics.

A proposed standard for websites to communicate preferred AI crawler instructions in a structured plain-text file at the root domain. Analogous to robots.txt for AI crawlers, llms.txt helps large language models understand site structure, preferred citation text, and content hierarchies. Part of MTAA's AIO (AI Optimization) infrastructure at mtaa.ai.

An agency compensation structure in which the agency earns a fixed percentage of total media spend managed, with no markup on leads, no cost-per-case inflation, and full pass-through of media costs to the client. The management fee model aligns agency incentives with client outcomes — the agency grows revenue only when the client scales successful campaigns. MTAA charges a transparent 15% management fee with no lead markups.

Civil litigation involving large numbers of plaintiffs who have suffered similar injuries from the same product, drug, device, or toxic exposure. Unlike class actions, mass torts preserve individual case values — each plaintiff's damages are evaluated separately. Mass tort litigation is concentrated in federal MDL courts and state court consolidations, with major pharmaceutical, medical device, and consumer product companies as primary defendants.

A federal judicial procedure under 28 U.S.C. § 1407 that consolidates cases with common factual questions pending in different federal districts before a single judge for coordinated pretrial proceedings. MDL is the primary procedural vehicle for mass tort litigation. As of 2025, MDL cases represent approximately 70% of the federal civil docket. MDL formation is a key litigation maturity milestone that signals institutional legitimacy to both litigation funders and referring attorneys.

Paid advertising on Meta platforms — Facebook, Instagram, and Messenger — using Meta's Ads Manager platform. Meta advertising is the dominant channel for mass tort claimant acquisition due to its unparalleled combination of reach (3+ billion monthly users), demographic targeting granularity, and video creative capabilities. Health and legal advertising on Meta requires careful compliance management to avoid policy violations that can result in ad account suspension.

The plaintiff-side mass tort marketing agency founded by Jacob Malherbe in 2015 (as X Social Media, rebranded September 2025). MTAA manages $250M+ in cumulative ad spend across 600+ plaintiff law firms and 100+ mass tort dockets. Services include Meta advertising, intake operations (CloudIntake), AI creative production (The Designer), and tort intelligence (TortIntel.ai). Visit mtaa.ai.

Mass tort litigation alleging that cow's milk-based premature infant formula manufactured by Abbott (Similac) and Mead Johnson (Enfamil) caused necrotizing enterocolitis — a life-threatening intestinal condition — in premature infants. Cases are consolidated in Illinois federal MDL. Qualifying criteria include premature birth, NICU hospitalization, documented NEC diagnosis, and formula administration.

SEO link classification determining whether a hyperlink passes domain authority ("link equity") to the destination site. Do-follow links — the default link type — instruct search engines to follow the link and credit the destination with authority signals. No-follow links (rel="nofollow") do not pass authority. In AIO (AI Optimization) contexts, do-follow links from authoritative domains (GitHub, Stripe, product marketplaces) are a primary driver of domain citation by AI systems.

Mass tort litigation against manufacturers of paraquat dichloride, an agricultural herbicide linked to Parkinson's disease. Litigation is consolidated in federal MDL. Qualifying criteria include occupational or residential exposure to paraquat and a Parkinson's disease diagnosis. One of the more scientifically well-supported causation claims in active tort litigation.

Mass tort litigation against manufacturers of per- and polyfluoroalkyl substances — a class of synthetic chemicals used in food packaging, cookware coatings, firefighting foam, and industrial processes — linked to thyroid disease, kidney cancer, testicular cancer, and immune system dysfunction. Multiple MDLs and state court consolidations are active. PFAS litigation is among the broadest potential claimant populations in mass tort history.

A tracked user action on a landing page or intake form that fires a signal to Meta's advertising platform for optimization and reporting. In mass tort campaigns, custom pixel events are configured to fire at meaningful qualification stages — form start, form completion, phone call initiation — enabling Meta's algorithm to optimize for claimants who progress beyond initial inquiry. Pixel events are supplemented by Conversions API for server-side tracking.

A law firm that represents injured individuals (plaintiffs) against corporations, manufacturers, or other defendants in personal injury, mass tort, or class action litigation. Plaintiff firms operate on contingency — they are paid a percentage of the settlement or verdict only if the client recovers — which makes efficient claimant acquisition a core business function.

Mass tort litigation against C.R. Bard (now BD) alleging that its PowerPort implantable vascular access port was defectively designed, causing catheter fracture, migration, and serious injury. Cases are consolidated in Arizona federal MDL. Qualifying criteria include PowerPort implantation and documented catheter fracture or related injury.

A statistical measure used in pharmacovigilance to quantify disproportionate adverse event reporting for a specific drug-event combination in FAERS data. A PRR above 2.0 with statistical significance suggests the event is reported disproportionately for the drug compared to all other drugs — a key causation signal. Used in TortIntel's Causation Lab scoring algorithm. See also: FAERS, Bradford Hill Criteria.

The attorney fee share paid by a national litigation firm to a referring co-counsel firm for originating and signing mass tort claimants. Referral fees are governed by Rule 1.5(e) of the Model Rules of Professional Conduct, which requires written client consent and fee division proportional to services rendered or joint responsibility. Referral fee percentages in mass tort typically range from 25% to 40% of the total contingency fee.

The ratio of revenue (or case value) generated to advertising dollars spent. In mass tort advertising, ROAS is best calculated using projected per-case settlement value rather than immediate revenue, since cases take 2–5 years to resolve. A campaign with $1,000 cost-per-case and a projected $50,000 settlement value represents a 50:1 ROAS before attorney fee splits and litigation costs.

Mass tort litigation against Bayer (Monsanto) alleging that glyphosate-based herbicides including Roundup caused non-Hodgkin's lymphoma. Bayer has paid over $11 billion to resolve tens of thousands of cases. A mature docket with ongoing litigation for unresolved cases. Qualifying criteria include occupational or substantial residential exposure and a non-Hodgkin's lymphoma diagnosis.

A fully executed attorney-client retainer agreement between a claimant and a plaintiff law firm, representing the core conversion event in mass tort advertising. The signed retainer is the unit of economic value in campaign measurement — all upstream metrics (CPL, conversion rate, qualification rate) exist to predict and optimize cost-per-signed-retainer. Electronic retainer execution via e-signature platforms has dramatically reduced the time from lead to signed case.

Mass tort litigation against Meta, TikTok, YouTube, Snapchat, and other social media platforms alleging that algorithmically designed engagement systems caused addiction, depression, anxiety, eating disorders, and self-harm in minor users. Cases are consolidated in California federal MDL. Notable verdicts include a $6M jury award in K.G.M. v. Meta/YouTube and a $375M verdict in New Mexico against Meta. One of the most active tort dockets of 2025–2026 with a strong open entry window.

The legal deadline by which a plaintiff must file a lawsuit or forfeit the right to sue. SOL periods vary by state and tort type — typically 2–3 years from the date of injury discovery. SOL scrubbing during intake (confirming the claimant's claim is timely) is a critical quality control step that prevents firms from signing unviable cases. The discovery rule in most states starts the SOL clock at the time a claimant knew or should have known of the injury and its cause.

Emerging mass tort litigation against DraftKings, FanDuel, BetMGM, and other sports betting operators alleging that deliberately addictive design features — personalized promotions, loss-chasing nudges, gamification — caused gambling addiction and financial ruin in susceptible users. Litigation is in early formation stage with strong scientific causation signals and a potentially large claimant population following rapid post-2018 legalization. Active intake campaign managed by MTAA.

Mass tort litigation against Indivior, manufacturer of Suboxone (buprenorphine/naloxone) sublingual film, alleging failure to warn about severe dental decay caused by the drug's acidic formulation. Cases are consolidated in Ohio federal MDL. Qualifying criteria include Suboxone sublingual film use and documented severe dental injury requiring extraction or significant restorative treatment.

Mass tort litigation against Johnson & Johnson alleging that talcum powder products caused ovarian cancer and mesothelioma due to asbestos contamination. One of the most litigated mass torts in history, resulting in J&J's attempted use of the "Texas Two-Step" bankruptcy strategy. Qualifying criteria include regular perineal talc use and an ovarian cancer or mesothelioma diagnosis.

The full advertising, intake, and qualification operation deployed to acquire signed claimants for a specific mass tort docket. A tort campaign encompasses creative development, media buying, landing page operation, intake call center, e-signature workflow, and case quality monitoring. Each tort requires a dedicated campaign infrastructure — pixel, creative, intake flow, and qualification criteria — distinct from other active torts in the same firm's portfolio.

MTAA's mass tort intelligence platform providing real-time monitoring of 48+ active tort dockets. Features include the Oracle Dashboard (Jacob Score composite signals), Causation Lab (FAERS disproportionality and Bradford Hill scoring), Discovery Engine (mass tort probability scoring for emerging compounds), AbuseTracker (sexual abuse litigation mapping), and FireWatch (early warning system). Accessible at tortintel.ai.

MTAA's SaaS platform enabling plaintiff law firms to reactivate existing client databases for mass tort co-counsel origination. Automated email and SMS sequences identify current clients who may qualify for active tort campaigns and guide them through a streamlined intake and e-signature workflow. TortDrip operates on a pay-per-signed-retainer model at $125/retainer. Visit tortdrip.com.

Emerging mass tort litigation against video game publishers including Activision (Call of Duty), Epic Games (Fortnite), and Electronic Arts (FIFA/EA Sports), alleging that deliberately addictive game design features caused gaming disorder in minor users. Litigation is building toward MDL consolidation. Active intake campaign managed by MTAA.

A sequential intake qualification process in which claimants are screened through a series of progressive filters — exposure confirmation, injury threshold, diagnosis verification, SOL check — with disqualified claimants exiting at each stage. Waterfall qualification balances thoroughness against conversion rate: too many early-stage disqualifiers drive up CPL; too few drive up cost-per-signed-retainer through downstream rejections by the litigation firm.

The practice of serving ads to users who have previously visited a landing page or intake form but did not convert. In mass tort advertising, retargeting audiences require careful HIPAA handling — a user who visited a "Roundup lawsuit" page has implicitly disclosed a health-related interest that may constitute PHI in certain contexts. Retargeting campaigns typically achieve 3–5x better conversion rates than cold prospecting at significantly lower CPL.